Rachael B. Turner, M.D., Ph.D.
Gynecologic Cancer , Obstetrics & Gynecology , Hematology & Oncology , General Obstetrics & Gynecology , Cancer
Contact
Rachael B. Turner, M.D., Ph.D.
View Contact & SchedulingLocations
Lattimore Medical Center
125 Lattimore Road, West Entrance, Suite 258
Rochester, NY 14620
Highland Hospital
1000 South Avenue
Rochester, NY 14620
About Me
Dr. Turner's special interests are women's cancers, including fallopian, ovarian, uterine and cervical. She is also interested in immune therapies for cancer. Dr. Turner is committed to providing personalized cancer care with compassion and dedication.
During her free time, Dr. Turner enjoys spending time with her husband and sons, running and hiking.
Certified Specialties
Internal Medicine - American Board of Internal Medicine
Medical Oncology - American Board of Internal Medicine
Faculty Appointments
Assistant Professor - Department of Medicine, Hematology/Oncology (SMD)
Assistant Professor - Department of Obstetrics and Gynecology (SMD) - Joint
Credentials
Residency & Fellowship
Fellowship, Hematology & Oncology, University of Rochester Medical Center. 2015 - 2018
Residency, Internal Medicine, University of Rochester Medical Center. 2014 - 2015
Internship, Internal Medicine, University of Rochester Medical Center. 2013 - 2014
Education
MD | SUNY at Buffalo-School of Medicine & Biomedical Sciences (USA). 2013
Awards
Internal Medicine Department Faculty Pilot Award. 2020 - 2021
Technology Development Fund Grant. 2019 - 2020
W.G Stuber Research Award. 2019 - 2020
Wilmot Fellowship Award. 2018
Conquer Cancer Foundation/Women who Conquer Cancer- Young Investigator Award. 2018
Best Overall Poster Presentation for HE4 in Ovarian Cancer Immune Suppression Poster Presentation. 2017
Harold Brody Award for Translational Research. 2011
Honorable Mention for poster presentation on Chronic Chemoimmunotherapy etc... 2010
Breast Cancer Pre-doctoral Traineeship Award. 2009 - 2011
Guy A. Bailey Outstanding Senior Award. 2005
Phi Beta Kappa National Honor Society. 2005
Tri-Beta Honor Society. 2004
Publications
Journal Articles
Rowswell-Turner R; Singh R; Urh A; Yano N; Kim K; Khazan K; Pandita, R; Sivagnanalingam U; Hovanesian V; James N; Ribeiro J; Kadambi S; Linehan D; Moore R.
J Immunol. 2021; .
Development of Potent Forchlorfenurone Analogs and Their Cytotoxic Effect in Cancer Cell Lines.
Kim KK; Singh RK; Khazan N; Kodza A; Singh NA; Jones A; Sivagnanalingam U; Towner M; Itamochi H; Turner, R; Moore RG.
Sci Rep. 2020; 10(1): 3241.
Role of trypsin and protease-active receptor-2 in ovarian cancer.
Kim KK; Turner R; Khazan N; Kodza A; Jones A; Singh RK; Moore RG.
PLOS One. 2020; 15(5): e0232253.
The biomarker HE4 (WFDC2) promotes a pro-angiogenic and immunosuppressive tumor microenvironment via regulation of STAT3 target genes.
James NE; Emerson JB; Borstadt; Beffa L; Liver MT; Hovanesian V; Urh A; Singh RK; Rowswell-Turner R; DiSilvestro PA; Ou J; Moore RG; Ribeiro JR.
Sci Rep. 2020; 10(1): 8558.
Novel small molecule MEK inhibitor URML-3881 enhances cisplatin sensitivity in clear cell ovarian cancer.
Rowswell-Turner R; Rutishauser J; Kim KK.
Translat Oncol. 2019; 12(7): 914-924.
James NE, Oliver MT, Ribeiro JR, Cantillo E, Rowswell-Turner RB, Kim KK, Chichester CO, DiSilvestro PA, Moore RG, Singh RK, Yano N, Zhao TC
Frontiers in pharmacology.. 2019 10 :216. Epub 03/19/2019.
HE4 suppresses the expression of osteopontin in mononuclear cells and compromises their cytotoxicity against ovarian cancer cells. Clin Exp Immunol. Epub ahead of print.
James, N.E.; Cantillo, E. ;Oliver, M.T.; Rowswell-Turner, R.B.
2018; .
Novel small molecule MEK inhibitor URML-3881 enhances cisplatin sensitivity in clear cell ovarian cancer. Manuscript submitted for publication.
Rowswell-Turner R, Rutishauser J, Kim KK et al.
2018; .
Treatment of chronic lymphocytic leukemia in older adults.
Rowswell-Turner, R.B; and Barr, P.
J Geriatric Oncology. 2017; 8(5): 315-319.
Chemoimmunotherapy as long-term maintenance therapy for cancer.
Egilmez, N.K.; Harden, J.L.; Rowswell-Turner, R.B.
Onco Immunology. 2012; 1(4): 1-3.
2012. Magnetic resonance spectroscopy of adult thalamic glioblastoma multiforme. N Am J Med Sci. 5(1):51-54.
Li, P.; Liu, Y.; Rowswell-Turner,R. B.; Esfahani, F.
2012; .
Chronic chemoimmunotherapy achieves cure of spontaneous murine mammary tumors via persistent blockade of posttherapy counter-regulation.
Rowswell-Turner, R.B.; Harden, J.L.; Nair,R.E;, Gu,T.; Kilinc,M.O.; Egilmez, N.K.
J Immunology. 2011; 187(8): 4109-18.
Dichotomous effects of IFN-y on dendritic cell function determine the extent of IL-12-driven antitumor T-cell immunity.
Harden, J.L.; Gu, T.; Kilinc, M.O.; Roswell-Turner, R.B.; Virtuoso, L.P.; Egilmez, N.K.
J Immunology. 2011; 187(1): 126-32.
Central Role of IFNgamma-indoleamine 2,3- dioxygenase axis in regulation of interleukin- 12- mediated antitumor immunity.
Gu, T.; Roswell-Turner, R.B.; Kilinc, M.O.; Egilmez, N.K.
Cancer Res. 2010; 70(1): 129-38.
Activated CD8+ T-effector/memory cells eliminated CD4+CD25+Foxp3+ T- suppressor cells from tumors via FasL mediated apoptosis
Kilinc, M.O.; Roswell-Turner, R.B.; Gu, T.; Virtuoso, L.P.; Egilmez, N.K.
J Immunology. 2009; 183(12): 7656-60.
Ratings & Comments
At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information. Learn more about our survey process.
Ratings
During this visit, did this provider spend enough time with you?
During this visit, did this provider show respect for what you had to say?
During this visit did this provider give you easy to understand information about these health questions or concerns?
During this visit, did this provider listen carefully to you?
During this visit, did this provider explain things in a way that was easy to understand?
Patient Comments
Dr Turner patient and thorough
Jan 16, 2024
Dr Turner always includes me in deciding my course of treatment and methods of handling side effects like anemia and fatigue
Sep 20, 2023
Dr.Turner was very helpful.
Aug 10, 2023
Dr Turner told me of possible down the road treatments when I asked about them.
May 21, 2023
Very helpful
Apr 27, 2023
Very good
Apr 26, 2023
I understood clearly what she told me
Feb 23, 2023
I feel very good with this provider & the new medical regimen.
Jan 20, 2023
I appreciated meeting with the doctor. She was friendly and obviously well-informed about my condition. And she definitely didn't 'mince words' in describing the future possibilities...I needed that!
Jan 12, 2023
I feel confident in this new team because of how thoroughly Dr Turner and Resident explained my situation and the treatment planned
Dec 04, 2022
Happy w/every aspect of visit
Oct 23, 2022
I have been extremely happy with my care providers! They rock.
Jun 02, 2022
Dr. Turner has gone above and beyond with taking time to listen, explain and discuss my treatment options and prognosis. I feel fortunate to have her overseeing my care during this challenging time.
Apr 24, 2022
Excellence always
Mar 12, 2022
Provider has always been excellent. [...]
Feb 14, 2022